Pharmaron acquires clinical CRO

By Melissa Fassbender contact

- Last updated on GMT

Pharmaron acquires clinical CRO SNBL CPC
Pharmaron has acquired a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, continuing its strategy of becoming a full service R&D service provider.

The Baltimore, Maryland-based Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (SNBL CPC) specializes in Phase I-II trials, including TQT/Phase 1 QT de-risking, first-in-human (FIH), Japanese Bridging and Phase II Proof of Concept (POC) studies in various therapeutics areas.

Following the transaction, the current shareholder, Shin Nippon Biomedical Laboratories, Ltd., will retain a minority stake in the business.

According to the company, the strategic acquisition brings Pharmaron one-step closer “to offering a full spectrum of R&D services​.”

Mr. Larry Lou, President and COO of Pharmaron commented in a release, “Once integrated and further developed, the new clinical platform will fuel the corporate engine for business growth in a sustainable manner​.”

In January, Pharmaron also acquired Xcelerton​ to further support early discovery, preclinical and clinical development with expanded radiolabeled science capabilities.

Financial terms of the transaction were not disclosed.

Pharmaron is not providing any additional comment at this time.

(Feature image: iStock/macgyverhh)

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers